CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor conferences: Piper Sandler 36th Annual Healthcare ConferenceRam Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Tuesday, Decemb ...

-REWRITE study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of KRRO-110 -First participant dosing anticipated in the first quarter of 2025 -Interim readout expected in second half of 2025 and completion of Phase 1/2a study anticipated in 2026 CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA ...

CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:00 a.m. GMT. Vineet Agarwal, Chief Financial Officer, and Kemi Olugemo, M.D., FAAN, Chief Medical O ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | --- | --- | --- | |---------------------------|-----------|-------------------------------------------------------| | | | | | | Trading | | | Title of each class | Symbol(s) | Name of each exchange on which registered | FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

财务数据 - 截至2024年9月30日现金、现金等价物和有价证券为1.691亿美元相比2023年12月31日的1.661亿美元[6] - 2024年第三季度研发费用为1600万美元较2023年同期的1400万美元增加[7] - 2024年第三季度一般和管理费用为730万美元较2023年同期的510万美元增加[8] - 2024年第三季度净亏损为2100万美元较2023年同期的1850万美元增加[9] 合作与收益 - 与诺和诺德合作开发多达两个针对心脏代谢疾病的靶点可获得高达5.3亿美元的前期、开发和商业里程碑付款等[4] 临床研究计划 - 预计2025年第一季度对KRRO - 110进行首位参与者给药[5] - 预计2025年下半年获得KRRO - 110在PiZZ患者中的1/2期临床研究中期结果[5] - 预计2026年完成KRRO - 110的1/2期临床研究[5] - 提交KRRO - 110在澳大利亚1/2期临床研究的监管文件[3] 组织架构调整 - 成立临床咨询委员会并任命新的董事会和领导成员[3]

-Regulatory filing of Phase 1/2 clinical study for Alpha-1 Antitrypsin Deficiency (AATD) submitted to Australian Bellberry Human Research Ethics Committee (HREC) -Clinical Advisory Board of lung and liver experts formed to support development of KRRO-110 -First participant dosing anticipated in first quarter of 2025 -Interim readout expected in second half of 2025 and completion of Phase 1/2 study anticipated in 2026 CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), ...

Shares of Korro Bio, Inc. (KRRO) have gained 6.7% over the past four weeks to close the last trading session at $39.76, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $135 indicates a potential upside of 239.5%. The mean estimate comprises five short-term price targets with a standard deviation of $42.13. While the lowest estimate of $95 indicates a 138.9% increase from the cur ...

CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced one oral and two poster presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal taking place on October 6-9, 2024. Venkat Krishnamurthy, Ph.D., Senior Vice President, Head of Platform at Korro, will deliver an oral ...

CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor and scientific conferences: 2024 Wells Fargo Healthcare Conference Chief Executive Officer and President, Ram Aiyar, Ph.D., and Chief Financial Officer, Vineet Agarwal, will participate ...

新型基因药物平台 - 公司正在开发一种新型基因药物平台,利用RNA编辑技术来治疗罕见和常见疾病[102][103][104] - 公司最先进的项目是KRRO-110,用于治疗α1抗胰蛋白酶缺乏症,正在进行临床前开发,计划于2024年下半年提交监管申请,并于2025年下半年获得临床数据[105] 资金筹集与支出 - 公司自成立以来一直通过发行股票等方式筹集资金,截至2024年6月30日已筹集约4.11亿美元[106][109] - 公司预计未来会持续大幅增加研发支出,以推进管线项目的临床开发[115][116][117] - 公司还将承担更多作为上市公司的运营成本,如合规、保险和投资者关系等[107][119] 研发费用 - 研发费用同比增加4.0百万美元，主要由于准备KRRO-110首次人体试验导致发现、临床前和合同制造成本增加2.4百万美元[125] - 研发费用同比增加2.9百万美元，主要由于准备KRRO-110首次人体试验导致发现、临床前和合同制造成本增加2.4百万美元，人员相关费用增加2.5百万美元，设施费用增加1.9百万美元[125] 一般及行政费用 - 一般及行政费用同比增加1.7百万美元，主要由于员工相关费用增加0.8百万美元，信息技术、设施和其他费用增加0.8百万美元[129] - 一般及行政费用同比增加4.2百万美元，主要由于员工相关费用增加1.5百万美元，信息技术和其他费用增加1.1百万美元，设施费用增加0.8百万美元，专业服务费用增加0.8百万美元[129] 其他收益 - 其他收益净额同比增加1.5百万美元，主要由于利息收入增加1.5百万美元[130] - 其他收益净额同比增加2.9百万美元，主要由于利息收入增加2.9百万美元[130] 现金及现金等价物 - 截至2024年6月30日，公司拥有1.878亿美元的现金、现金等价物和可供出售证券[131] - 公司预计现有现金、现金等价物和可供出售证券将足以支持运营费用和资本支出需求至2026年下半年[133] - 截至2024年6月30日，公司现金及现金等价物为1.878亿美元，主要为银行存款、货币市场基金和美国国债等[147] 未来资金需求 - 公司未来资金需求取决于多个因素,包括持续建设OPERA平台、临床试验进展、潜在收购或合作、监管审批、人员扩张等[136] - 公司预计将通过股权融资、债务融资、合作等方式筹集资金[137] 会计政策 - 公司无重大会计估计变更[143] - 最近会计准则变更的描述包含在财务报表附注中[144] - 公司为新兴成长公司和小报告公司，可享受相关豁免政策[145][146] - 公司主要业务和员工位于美国，外币交易影响较小[148]